Leadership

Andrew D. Goldberg, MD, was appointed Chief Executive Officer of AchieveRx in April 2026. Andrew is a physician, healthcare investor, and governance leader who has spent his career at the intersection of clinical medicine and commercial execution. Most recently, he served as a Portfolio Manager at Marshall Wace and previously as a Partner at Vivo Capital, a healthcare-focused investment firm. Earlier in his career, he was a consultant at McKinsey & Company in Silicon Valley, advising pharmaceutical, biotechnology, and medical device companies. He has served as a board director or observer at 19 life sciences companies, including Tarsus Pharmaceuticals (Nasdaq: TARS) through FDA approval and the national launch and commercialization of XDEMVY, Veradermics (NYSE: MANE) through its successful IPO, Inquis Medical through FDA approval and commercialization of the Aventus thrombectomy system, Elektrofi through its $900M acquisition by Halozyme Therapeutics (Nasdaq: HALO), Parse Biosciences through its acquisition by Qiagen (NYSE: QGEN), and Forge Biologics through its acquisition by Ajinomoto. As lead investor, he anchored the U.S. market transition for Verona Pharma (Nasdaq: VRNA), culminating in the $10.8B acquisition by Merck, and led the pre-IPO investment in Harmony Biosciences (Nasdaq: HRMY), which scaled WAKIX into a new category in sleep medicine. Dr. Goldberg is among the first physicians in the United States to earn dual board certification in Critical Care Medicine and Emergency Medicine. He served as an Instructor in Medicine at the Mayo Clinic, where he completed a Critical Care fellowship, after training in Emergency Medicine at LAC+USC. He has over 25 scientific publications including research on tobacco advertising, published in JAMA, that examined youth targeting and contributed to public-health initiatives that earned him the Oregon Governor’s Council Outstanding Achievement Award. Dr. Goldberg received his MD from The George Washington University School of Medicine and a post-doctoral diploma in translational science from the Mayo Graduate School.

Mark L. Rubinstein, MD is the Chief Medical Officer at AchieveRx, bringing more than two decades of experience in clinical medicine, scientific research and medical affairs leadership, with a strong focus on nicotine cessation and preventive medicine. Prior to joining AchieveRx, Mark served as the Head of Medical Affairs at Blip, where he spearheaded the company’s strategy to help smokers and vapers quit through FDA-approved medications and digital support tools. He was also Vice President of Global Scientific Affairs at Juul Labs, where he led efforts to prevent youth usage of nicotine products. Mark is Professor Emeritus of Pediatrics at the University of California, San Francisco (UCSF), where his NIH-funded research advanced understanding of adolescent nicotine addiction and smoking cessation interventions. He earned his MD from Yale School of Medicine, completed his Internal Medicine residency at Yale–New Haven Hospital, and is board certified in Internal Medicine and Adolescent Medicine.

Ben Halladay is the Chief Financial Officer at AchieveRx and has spent more than 15 years of financial management experience across commercial and launch environments. Before joining AchieveRx Ben served as the Chief Financial Officer of Esperion Therapeutics, a commercial-stage pharmaceutical company with more than $400 million in annual revenue. During his tenure, Esperion deleveraged its balance sheet and acquired Corstasis Therapeutics and its product Enbumyst. He led the finance workstream through the company’s sale to ARCHIMED for up to $1.1 billion. Earlier, Ben held positions at Pfizer Inc., where he worked on Lipitor and Chantix in the Primary Care business unit, and at National Oilwell Varco, a Fortune 500 global industrial company. He holds an MBA from Fordham University and a BA from Syracuse University and is a Certified Public Accountant (inactive).

Erik Atkisson is the Chief Legal Officer at AchieveRx, bringing over 25 years of experience in the pharmaceutical and biotechnology industries. Erik has deep expertise in guiding the global development, launch, and commercialization of biopharmaceutical products, and has held senior legal positions at multiple clinical- and commercial-stage biopharmaceutical companies. Prior to AchieveRx, he served as General Counsel, Corporate Secretary, and Chief Compliance Officer at Rain Oncology, leading all legal matters including governance, IP, contracting, regulatory, privacy, and litigation. Earlier in his career, Erik served as General Counsel of Eiger BioPharmaceuticals and Chief Compliance Officer of Cytokinetics. He also held senior positions at Amneal Pharmaceuticals (formerly Impax Laboratories) and BioMarin Pharmaceutical. Erik holds a JD from Georgetown University Law Center, an MSc from the University of Edinburgh, and a BA from Harvard University.

Kaitlyn Tuson is the Senior Vice President, Marketing & Communications at AchieveRx and has spent more than 15 years building, launching and scaling healthcare brands at the intersection of public health, patient engagement, innovation and care delivery. Throughout her career, Kait has helped companies bring products and services to market across healthcare, including six pharmaceutical products, three of them blockbuster therapies. Her work has shaped brand and go-to-market strategy across more than 40 therapeutic areas globally, and she has led integrated communications and award-winning marketing campaigns that reached national audiences. Previously, Kait led marketing and communications for Weill Cornell Medicine’s clinical services organization, spanning 25 departments and more than 180 locations, where she drove digital transformation, telehealth and patient engagement initiatives. She holds a BA in Business, Communications and Digital Audiences from the W. P. Carey School of Business at Arizona State University.

Mark Zappia is the Senior Vice President, Commercial at AchieveRx, focused on sales, commercial operations, and market access. Mark brings nearly 20 years of commercial operations and finance leadership experience in specialty pharmaceuticals, with deep expertise in pre-commercial and launch strategy, commercial operations, and building commercial organizations from the ground up. Prior to joining AchieveRx, Mark was Vice President, Commercial Operations at Verona Pharma, where he was one of three original commercial leaders who built the commercial operations function and helped drive the launch of Ohtuvayre®, one of the best pulmonary launches in the history of pharma. Before that, he held a series of commercial strategy and finance leadership roles at Mayne Pharma, including VP Commercial Strategy. Earlier in his career, Mark held commercial operations, analytics, and finance roles at Circassia, Bioventus, and Sunovion Pharmaceuticals, building broad experience across respiratory, medical devices, and CNS markets. He holds an MS in Finance from Brandeis University and a BS in Accounting from Hartwick College.

Gloria Cosgrove is the Senior Vice President, Global Quality at AchieveRx and brings more than 30 years of Quality leadership experience across the biotechnology and pharmaceutical industries, helping companies build scalable, phase-appropriate Quality organizations and Quality Management Systems that support products from early clinical development through commercialization. Prior to joining AchieveRx, Gloria served as a strategic Quality consultant (SVP) to Bicara Therapeutics, helping shape the company’s Quality strategy and organizational structure as it advanced late-stage clinical development and prepared for future commercialization. She also served as Senior Vice President of Quality and later Senior Vice President of Quality & Technical Operations at Lyra Therapeutics. Prior to Lyra, Gloria served as Vice President of Global Quality at Seres Therapeutics, where she helped lead the company through FDA approval of the first microbiome therapeutic, VOWST™, while building a scalable Quality organization to support commercial manufacturing. Earlier in her career, she held a variety of Quality leadership roles at Boehringer Ingelheim, Regeneron Pharmaceuticals, and Synageva BioPharma. She attended Utah State University and University of Bridgeport majoring in Special Education and Psychology.

Ronald Dadino is the Senior Vice President, Chemistry, Manufacturing and Controls (CMC) and Supply Chain at AchieveRx and brings over 40 years of CMC and operations experience, with deep expertise in drug substance and drug product development, product commercialization and clinical/commercial product supply chains. Prior to joining AchieveRx, Ron was Executive Vice President, CMC and Supply Chain at Sling Therapeutics, where he was responsible for all pharmaceutical product development and the global clinical supply chain. He has also held a variety of executive management positions in both large and small pharmaceutical companies, as well as consulting for CMC related projects. Ron has a diverse background in CMC including product development and commercialization, technical operations and commercial manufacturing. He holds a BS in Pharmacy from the Philadelphia College of Pharmacy and Science and an MS in Pharmaceutical Quality Assurance/Regulatory Affairs from Temple University.

Lucian Iancovici, MD is a Managing Director at TPG, a leading global alternative asset management firm, where he has worked since January 2018. He brings extensive experience in digital health and life sciences investing, with previous roles as head of the Qualcomm Life Fund (a venture fund focused on digital health technologies) and as a general partner at dRx Capital (a joint venture launched by Novartis and Qualcomm). Lucian also formerly served as an associate at McKinsey & Company. He is a board-certified internal medicine physician who trained at Columbia University Medical Center and currently serves on the boards of Sionna Therapeutics, Ceribell, Sling Therapeutics, Ellodi Pharmaceuticals, and Anovo. He received a BA in Economics and an MD from Tufts University.

Jeffrey Farrow has served as Chief Financial Officer and Chief Strategy Officer of Tarsus Pharmaceuticals, Inc. since April 2023, where he has helped lead the ongoing commercial launch of XDEMVY® for Demodex blepharitis. Jeff has been Chief Financial Officer of four publicly traded biopharmaceutical companies, including three that were acquired for total transaction value of more than $9 billion. He previously served as Chief Financial Officer of Global Blood Therapeutics, Inc. from April 2016 until its acquisition by Pfizer for approximately $5.4 billion in December 2022, during which time the Company received FDA approval and commercially launched Oxbryta® for sickle cell disease. Prior to that, he served as Chief Financial Officer of ZS Pharma, Inc., acquired by AstraZeneca for approximately $2.7 billion in December 2015, and Chief Financial Officer of Hyperion Therapeutics, Inc. from January 2010 until its acquisition by Horizon Therapeutics for approximately $1.1 billion in May 2015, where he was part of the team that secured FDA approval and commercially launched RAVICTI® for urea cycle disorders. Earlier in his career, he held senior finance roles at Evotec AG and Renovis, Inc. (acquired by Evotec), and spent seven years in the audit practice of KPMG LLP. He holds a BA in business administration with a concentration in corporate finance from California State University at Fullerton and is a certified public accountant (inactive). Jeff currently serves on the Board of Directors of Clover Biopharmaceuticals, Ltd. and California Life Sciences (CLS).

Christopher Martin is an accomplished pharmaceutical commercial leader with over 25 years of expertise spanning sales, marketing, market access, operations, and business development. Most recently, he served as Chief Commercial Officer at Verona Pharma, a biopharmaceutical company acquired by Merck & Co. in October 2025 that specialized in developing innovative, inhaled therapies for chronic respiratory diseases. Chris previously served as Executive Director of Marketing at SK Life Science, where he was instrumental in developing the commercial and marketing strategy for launching XCOPRI® (cenobamate tablets), a novel CNS therapeutic. Earlier, he was Head of Marketing at Cempra Pharmaceuticals, where he led launch strategy and commercial planning for the company’s first product. Prior to that, he was with Salix Pharmaceuticals in roles of increasing responsibility, including leading the Xifaxan® marketing team. Chris currently serves on the boards of Oruka Therapeutics (Nasdaq: ORKA) and Edgewise Therapeutics (Nasdaq: EWTX). He received a BS in Financial Management from Clemson University.

Nancy R. Phelan has served as a member of our Board of Directors since January 2025. Nancy currently serves as Senior Vice President of Marketing & Analytics at Phathom Pharmaceuticals, a biopharmaceutical company focused on gastrointestinal diseases. She has served as a member of the board of directors of Medexus Pharmaceuticals, a specialty pharmaceutical company focusing on the therapeutic areas of oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology, since September 2023, and was previously an independent board member of FemmePharma Consumer Healthcare, a pharmaceutical company dedicated to developing treatment options to address diseases and disorders that disproportionately affect women. From May 2024 to October 2025, she served as Senior Vice President & Head of Customer Engagement at Trinity Life Sciences, a leader in strategy, insights and analytics for the life sciences industry. Prior to that, Nancy served as Senior Vice President of Indegene, a technology-led healthcare solutions provider. She also previously held roles of increasing responsibility with Novartis, a global leader in developing and delivering innovative medicines for serious diseases, including as Vice President, Business Transformation, Patient Engagement and Integrated Marketing Team Lead from April 2021 to May 2022 and Vice President, Patient and Specialty Services, Neuroscience from June 2002 to April 2021. She served as Chief Executive Officer and Secretary of Adhera Therapeutics, Inc., a company focused on the discovery, development, and commercialization of small molecule drugs, from April 2019 to June 2020 and as a director from October 2018 to June 2020. Nancy received a BA with Honors from Franklin & Marshall College and completed coursework towards an MBA from Villanova University. She also received certificates from Wharton Executive Education and the Harvard School of Public Health.

Aaron Royston, MD is a Managing Partner at venBio with more than 15 years of experience in life sciences investing, company formation, and clinical research. He has been instrumental in launching and investing in numerous venBio companies, including Apellis Pharmaceuticals, Akero Therapeutics, Harmony Biosciences, Ventyx BioSciences, RayzeBio and ViceBio, whose efforts have collectively contributed to seven FDA approvals. Prior to joining venBio, Aaron was a member of the investment team at Vivo Capital and previously worked at Bain & Company, where he counseled biotechnology companies on strategic and operational issues. In 2010, he was recognized by the United States White House as a Champion of Change for his work in Technology and Innovation. He received a BS in Biological Sciences from Duke University and his MD and MBA from the University of Pennsylvania.

Tom Sellig brings more than 30 years of global experience in the life sciences and pharmaceutical services industries. He is currently CEO of Adare Pharma Solutions, a global technology-driven Contract Development and Manufacturing Organization specializing in oral solid dosage forms. From 2019 to 2021 Tom served as Chief Executive Officer of LabConnect, a clinical trial laboratory services organization. Prior to LabConnect, Tom was Chief Commercial Officer at ConnectiveRx, where he was responsible for all commercial and customer-facing activity at the patient support and patient access company. Earlier, he was Senior Vice President of Global Sales at Patheon, where he played an integral role in the company’s sale to and integration with Thermo Fisher. Previously, he served as the Global Vice President of Sales and Client Services at Covance. Early in his career, Tom had a variety of sales and marketing leadership roles at Procter & Gamble, American Home Products, and Ascent Pediatrics. He received his BA in Economics from Vanderbilt University and an MBA from New York University.

Richard Stewart is a co-founder of AchieveRx and previously served as the Company’s President and Chief Executive Officer. He is a director on the AchieveRx Board of Directors and previously served as Chairman. Rick is also a founder and a director of Ricanto Limited, a pharmaceutical asset optimization company, since 2009. He has been Chairman and Chief Executive Officer of Renown Pharma Limited, a central nervous system company focused on Parkinson’s disease, since 2016. Prior to AchieveRx, Rick was Chairman and Chief Executive Officer of Huxley Pharmaceuticals, Inc., a single-purpose central nervous system company, during 2009, prior to Huxley Pharmaceuticals, Inc.’s acquisition by BioMarin Pharmaceutical Inc. Rick was Chief Executive Officer of Brabant Pharma Limited, a single-purpose central nervous system company, from 2013 to 2014 prior to Brabant Pharma’s acquisition by Zogenix Inc. He was a co-founder and Chief Executive Officer of Amarin Corporation plc, a central nervous system company focused on Parkinson’s disease and Huntington’s disease, from 2000 to 2007. Rick was a co-founder and Chief Financial Officer, and later Chief Business Officer, of SkyePharma plc, a drug delivery company specializing in controlled release formulations, and held such positions from 1995 to 1998. He holds a BS degree in Business Administration from the University of Bath.

Reid Waldman, MD is the Chief Executive Officer of Veradermics. Under his stewardship, he has positioned Veradermics for rapid growth by implementing a differentiated strategy centered on advancing therapeutics for under-innovated markets in aesthetics and dermatology. He has also successfully led the company through significant equity financings, and has advanced Veradermics’ lead asset, VDPHL01, a potential non-hormonal oral treatment for pattern hair loss, through positive Phase 2/3 results for men. Reid is a board-certified dermatologist with more than 10 years of clinical experience. Prior to founding Veradermics, he was a prolific researcher authoring more than 100 publications, including a textbook titled “Dermatology for the Primary Care Provider.” Reid has been the recipient of numerous accolades including the American Academy of Dermatology’s “Excellence in Patient Care” award. He earned his BA and his MD degrees from the University of Missouri–Kansas City 6-Year BA/MD Program and completed his dermatology residency with a “Distinction in Clinical Trials” at the University of Connecticut.